SciClone Pharmaceuticals, Inc. Reports Results From ZADAXIN Proof-Of-Concept Liver Cancer Trial

SAN MATEO, CA -- (MARKET WIRE) -- 12/21/2005 -- SciClone Pharmaceuticals (NASDAQ: SCLN) today reported data from its small, phase 2 proof-of-concept hepatocellular carcinoma (liver cancer) trial indicating a trend toward positive survival benefit in patients treated with ZADAXIN® plus trans arterial chemo-embolization (TACE) compared with patients treated with TACE alone. Specifically, a median survival of 994 days was observed for the 12 patients who received ZADAXIN plus TACE, compared with a median survival of only 399 days for the 13 patients who received TACE alone, the control arm. No difference was observed in tumor response between the treatment groups.

Back to news